Sepsis
Welcome,         Profile    Billing    Logout  
 53 Companies   51 Products   51 Products   62 Mechanisms of Action   0 Trials   1105 News 


«12345678910111213...1920»
  • ||||||||||  Trial completion, Trial primary completion date:  RGNOSIS: Ecological Effects of Decolonisation Strategies in Intensive Care (clinicaltrials.gov) -  Nov 1, 2017   
    P3,  N=8665, Completed, 
    Recruiting --> Completed | Initiation date: Mar 2013 --> May 2012 Recruiting --> Completed | Trial primary completion date: Jun 2017 --> Oct 2017
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion:  Effects of Endotoxin in Normal Human Volunteers (clinicaltrials.gov) -  Oct 18, 2017   
    P1,  N=198, Completed, 
    Active, not recruiting --> Completed | N=12000 --> 7813 | Trial primary completion date: Dec 2016 --> Jun 2016 Active, not recruiting --> Completed
  • ||||||||||  Trial completion, Enrollment change:  Preemptive Resuscitation for Eradication of Septic Shock (clinicaltrials.gov) -  Oct 4, 2017   
    P=N/A,  N=142, Completed, 
    Recruiting --> Completed | Trial primary completion date: Dec 2016 --> May 2017 Terminated --> Completed | N=43 --> 142
  • ||||||||||  Actimmune (interferon gamma-1 b) / Clinigen, Amgen
    Trial completion, Enrollment change, IO biomarker:  The Effects of Interferon-gamma on Sepsis-induced Immunoparalysis (clinicaltrials.gov) -  Sep 29, 2017   
    P3,  N=4, Completed, 
    Terminated --> Completed | N=43 --> 142 Recruiting --> Completed | N=20 --> 4
  • ||||||||||  Trial completion, Enrollment change:  Study to Evaluate the Effectiveness of the Initial Specimen Diversion Device (clinicaltrials.gov) -  Aug 11, 2017   
    P=N/A,  N=971, Completed, 
    N=4444 --> 200 | Recruiting --> Terminated | Trial primary completion date: Dec 2015 --> May 2015; Lack of enrollment Recruiting --> Completed | N=5308 --> 971
  • ||||||||||  Trial completion, Trial primary completion date:  EIDECS: End-of-life Decision-making in Patients With Sepsis-related Organ Failure (clinicaltrials.gov) -  Aug 9, 2017   
    P=N/A,  N=174, Completed, 
    Recruiting --> Completed | N=5308 --> 971 Active, not recruiting --> Completed | Trial primary completion date: Aug 2016 --> Sep 2014
  • ||||||||||  Vabomere (meropenem/vaborbactam) / Melinta Therap
    Trial completion, Enrollment change, Trial primary completion date:  Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults (clinicaltrials.gov) -  Aug 8, 2017   
    P3,  N=77, Completed, 
    Active, not recruiting --> Completed | Trial primary completion date: Aug 2016 --> Sep 2014 Recruiting --> Completed | N=150 --> 77 | Trial primary completion date: Dec 2017 --> Jul 2017
  • ||||||||||  Trial completion:  ADSeS: Examination of ADMA Serum Level and DDAH II (clinicaltrials.gov) -  Aug 3, 2017   
    P=N/A,  N=120, Completed, 
    Recruiting --> Completed | N=150 --> 77 | Trial primary completion date: Dec 2017 --> Jul 2017 Active, not recruiting --> Completed
  • ||||||||||  clonidine / Generic mfg.
    Trial primary completion date:  CATACHOC: Upregulation of Alpha-1 Receptors Upon Septic Shock? (clinicaltrials.gov) -  Jul 28, 2017   
    P2/3,  N=40, Terminated, 
    Initiation date: Dec 2006 --> Mar 2007 Trial primary completion date: Aug 2014 --> Aug 2013
  • ||||||||||  tacrolimus intravenous / Generic mfg., mycophenolate mofetil / Generic mfg., sirolimus / Generic mfg.
    Trial completion:  Using mTOR Inhibitors in the Prevention of BK Nephropathy (clinicaltrials.gov) -  Jul 19, 2017   
    P=N/A,  N=41, Completed, 
    Trial primary completion date: Aug 2014 --> Aug 2013 Active, not recruiting --> Completed
  • ||||||||||  Phase classification:  High MAP in Septic Shock With Hypertension (clinicaltrials.gov) -  Jul 6, 2017   
    P=N/A,  N=19, Completed, 
    Phase classification: P1/2 --> P=N/A Phase classification: P4 --> P=N/A
  • ||||||||||  ceftriaxone / Generic mfg.
    Trial completion, Enrollment change, Trial primary completion date:  PHANTASi: Prehospital Antibiotics Against Sepsis Trial (clinicaltrials.gov) -  Jun 15, 2017   
    P=N/A,  N=2672, Completed, 
    Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Jun 2017 Recruiting --> Completed | N=2200 --> 2672 | Trial primary completion date: Jun 2016 --> Jun 2017
  • ||||||||||  simvastatin / Generic mfg.
    Enrollment change:  Statin Therapy in the Treatment of Sepsis (clinicaltrials.gov) -  Jun 14, 2017   
    P2/3,  N=18, Completed, 
    Recruiting --> Completed | N=2200 --> 2672 | Trial primary completion date: Jun 2016 --> Jun 2017 N=13 --> 18
  • ||||||||||  Trial completion, Trial primary completion date, Gram negative:  Gram Negative Bacteremia, Risk Factors for Failure of Therapy (clinicaltrials.gov) -  Jun 9, 2017   
    P=N/A,  N=600, Completed, 
    Trial primary completion date: Dec 2016 --> Dec 2025 Recruiting --> Completed | Trial primary completion date: Dec 2020 --> May 2016
  • ||||||||||  dexmedetomidine / Generic mfg.
    Clinical:  Dexmedetomidine on Microcirculation in Septic Shock (clinicaltrials.gov) -  May 17, 2017   
    P4,  N=30, Completed, 
    Recruiting --> Completed | Trial primary completion date: Dec 2020 --> May 2016 Recruiting --> Completed
  • ||||||||||  Solu-Cortef (hydrocortisone sodium succinate injection) / Pfizer
    Enrollment closed, Trial primary completion date:  ADRENAL: ADjunctive coRticosteroid trEatment iN criticAlly ilL Patients With Septic Shock (clinicaltrials.gov) -  May 3, 2017   
    P4,  N=3800, Active, not recruiting, 
    Recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Jul 2017
  • ||||||||||  Trial completion, Enrollment change, Trial initiation date, Trial primary completion date:  Near Infrared Spectroscopy (St02) (clinicaltrials.gov) -  Apr 26, 2017   
    P=N/A,  N=186, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed | N=300 --> 186 | Initiation date: Sep 2008 --> Jan 2009 | Trial primary completion date: Sep 2016 --> Jan 2010
  • ||||||||||  Trial completion, Enrollment change, Trial initiation date, Trial primary completion date:  Endothelium in Severe Sepsis (clinicaltrials.gov) -  Apr 26, 2017   
    P=N/A,  N=910, Completed, 
    Active, not recruiting --> Completed | N=300 --> 186 | Initiation date: Sep 2008 --> Jan 2009 | Trial primary completion date: Sep 2016 --> Jan 2010 Recruiting --> Completed | N=600 --> 910 | Initiation date: Jun 2008 --> Mar 2008 | Trial primary completion date: Jan 2017 --> May 2013
  • ||||||||||  Trial completion:  Balanced Salt Solution VS. Normal Saline Solution in Septic Shock (clinicaltrials.gov) -  Apr 26, 2017   
    P3,  N=60, Completed, 
    Recruiting --> Completed | N=600 --> 910 | Initiation date: Jun 2008 --> Mar 2008 | Trial primary completion date: Jan 2017 --> May 2013 Recruiting --> Completed
  • ||||||||||  Ventavis (iloprost) / Bayer, J&J, University of Copenhagen, Integrilin (eptifibatide) / Takeda
    Trial completion, Trial primary completion date:  CO-ILEPSS: Co-administration of Iloprost and Eptifibatide in Septic Shock Patients (clinicaltrials.gov) -  Apr 24, 2017   
    P2,  N=18, Completed, 
    Recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Aug 2015 --> Aug 2016
  • ||||||||||  Trial initiation date, Trial primary completion date:  DAMSEL2: Dose Assessment of Melatonin in Sepsis Trial (clinicaltrials.gov) -  Apr 21, 2017   
    P1/2,  N=0, Withdrawn, 
    Recruiting --> Completed | Trial primary completion date: Aug 2015 --> Aug 2016 Initiation date: Dec 2014 --> Apr 2017 | Trial primary completion date: Dec 2014 --> Jun 2019
  • ||||||||||  Trial termination, Trial primary completion date:  Evaluation of the Patient Safety Screening Tool (PSST) for Sepsis (clinicaltrials.gov) -  Apr 20, 2017   
    P=N/A,  N=221, Terminated, 
    Initiation date: Dec 2014 --> Apr 2017 | Trial primary completion date: Dec 2014 --> Jun 2019 Enrolling by invitation --> Terminated | Trial primary completion date: May 2009 --> Mar 2010; The study design failed and the data was not able to be analyzed.
  • ||||||||||  Omegaven (omega-3 long-chain polyunsaturated fatty acids) / Fresenius Kabi
    Enrollment change, Trial termination, Trial primary completion date:  FOILED: Fish OIL Optimal dosE Determination Study (clinicaltrials.gov) -  Apr 19, 2017   
    P2,  N=7, Terminated, 
    Enrolling by invitation --> Terminated | Trial primary completion date: May 2009 --> Mar 2010; The study design failed and the data was not able to be analyzed. N=21 --> 7 | Recruiting --> Terminated | Trial primary completion date: Dec 2017 --> Apr 2017; Low enrollment/ expiration of the grant
  • ||||||||||  Enrollment change, Trial withdrawal:  Early Goal Directed Therapy in Sepsis by Emergency Medical Services (clinicaltrials.gov) -  Apr 17, 2017   
    P=N/A,  N=0, Withdrawn, 
    N=21 --> 7 | Recruiting --> Terminated | Trial primary completion date: Dec 2017 --> Apr 2017; Low enrollment/ expiration of the grant N=200 --> 0 | Recruiting --> Withdrawn
  • ||||||||||  Trial completion, Enrollment change, Trial primary completion date:  Early Insulin and Development of ARDS (clinicaltrials.gov) -  Apr 10, 2017   
    P2,  N=18, Completed, 
    Trial primary completion date: Dec 2016 --> Dec 2017 Active, not recruiting --> Completed | N=90 --> 18 | Trial primary completion date: Sep 2012 --> Dec 2011
  • ||||||||||  Trial completion, Enrollment change, Trial primary completion date:  CD64 Measurement in Neonatal Infection and Necrotising Enterocolitis (clinicaltrials.gov) -  Apr 7, 2017   
    P=N/A,  N=59, Completed, 
    Phase classification: P3 --> P=N/A Recruiting --> Completed | N=150 --> 59 | Trial primary completion date: Jan 2010 --> Jun 2010